PT1675846E - Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona - Google Patents

Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona Download PDF

Info

Publication number
PT1675846E
PT1675846E PT04793893T PT04793893T PT1675846E PT 1675846 E PT1675846 E PT 1675846E PT 04793893 T PT04793893 T PT 04793893T PT 04793893 T PT04793893 T PT 04793893T PT 1675846 E PT1675846 E PT 1675846E
Authority
PT
Portugal
Prior art keywords
pyridin
trifluoromethylbenzyl
methanone
triazol
chlorophenyl
Prior art date
Application number
PT04793893T
Other languages
English (en)
Portuguese (pt)
Inventor
Susan Marie Reutzel-Edens
Alfio Borghese
David Scott Coffey
Pamela Kaye Footman
Steven Wayne Pedersen
Shella Lenyonga Tameze
Carsten Weber
Carsten Timpe
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PT1675846E publication Critical patent/PT1675846E/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicinal Preparation (AREA)
PT04793893T 2003-10-24 2004-10-12 Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona PT1675846E (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US51430003P 2003-10-24 2003-10-24

Publications (1)

Publication Number Publication Date
PT1675846E true PT1675846E (pt) 2010-04-20

Family

ID=34549327

Family Applications (1)

Application Number Title Priority Date Filing Date
PT04793893T PT1675846E (pt) 2003-10-24 2004-10-12 Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona

Country Status (28)

Country Link
US (1) US7381826B2 (https=)
JP (1) JP4959336B2 (https=)
KR (1) KR100848407B1 (https=)
CN (1) CN1863791B (https=)
AR (1) AR046131A1 (https=)
AT (1) ATE462700T1 (https=)
AU (1) AU2004285855B8 (https=)
BR (1) BRPI0415010B8 (https=)
CA (1) CA2542140C (https=)
CL (2) CL2009001310A1 (https=)
CR (1) CR8353A (https=)
DE (1) DE602004026333D1 (https=)
DK (1) DK1675846T3 (https=)
EA (1) EA008881B1 (https=)
EC (1) ECSP066517A (https=)
ES (1) ES2340772T3 (https=)
HR (1) HRP20100207T1 (https=)
IL (1) IL174926A0 (https=)
MA (1) MA28329A1 (https=)
MY (1) MY157375A (https=)
NO (1) NO335090B1 (https=)
NZ (2) NZ580480A (https=)
PE (1) PE20050481A1 (https=)
PT (1) PT1675846E (https=)
TW (1) TW200524906A (https=)
UA (1) UA82901C2 (https=)
WO (1) WO2005042515A1 (https=)
ZA (1) ZA200603234B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101568523A (zh) * 2006-12-20 2009-10-28 伊莱利利公司 用于制备{2-[1-(3,5-二-三氟甲基-苄基)-5-吡啶-4-基-1h-[1,2,3]三唑-4-基]-吡啶-3-基}·(2-氯苯基)甲酮的新中间体和方法
WO2009075778A2 (en) * 2007-12-06 2009-06-18 The Regents Of The University Of California Nonpeptidic inhibitors of cruzain
US8080568B1 (en) * 2010-06-29 2011-12-20 Ewha University - Industry Collaboration Foundation 2-pyridyl substituted imidazoles as therapeutic ALK5 and/or ALK4 inhibitors
CA2978736C (en) 2015-03-04 2023-11-07 Vanda Pharmaceuticals Inc. Dosing regimen of tradipitant
WO2017031215A1 (en) * 2015-08-17 2017-02-23 Eli Lilly And Company Process development of a pyridine-containing nk-1 receptor antagonist
CA3073998A1 (en) 2017-09-13 2019-03-21 Vanda Pharmaceuticals Inc. Improved treatment of atopic dermatitis with tradipitant
KR20250140655A (ko) * 2017-11-17 2025-09-25 반다 파마슈티칼즈, 인코퍼레이티드. 트라디피탄트를 이용한 위장 질환의 치료 방법
CN112218636B (zh) * 2018-06-08 2025-05-06 万达制药公司 使用川地匹坦进行治疗的方法
KR102863233B1 (ko) 2018-09-28 2025-09-22 반다 파마슈티칼즈, 인코퍼레이티드. 멀미에서의 트라디피탄트의 용도
US10821099B2 (en) 2018-09-28 2020-11-03 Vanda Pharmaceuticals Inc. Use of tradipitant in motion sickness
WO2020117811A1 (en) 2018-12-03 2020-06-11 Vanda Pharmaceuticals Inc. Method of treatment with tradipitant
JP2023515167A (ja) 2020-02-25 2023-04-12 バンダ・ファーマシューティカルズ・インコーポレイテッド トラジピタントによるアトピー性皮膚炎の改善された治療
WO2021195205A1 (en) 2020-03-26 2021-09-30 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
WO2023019084A1 (en) 2021-08-12 2023-02-16 Vanda Pharmaceuticals Inc. Treatment of gastric accommodation with tradipitant
US20240350469A1 (en) 2021-08-31 2024-10-24 Vanda Pharmaceuticals Inc. Treatment of lower respiratory tract infection with tradipitant
CN120641099A (zh) 2022-12-21 2025-09-12 万达制药公司 使用曲地匹坦的治疗方法
EP4599831A1 (en) 2024-02-09 2025-08-13 Vanda Pharmaceuticals Inc. Treatment of gastroparesis with tradipitant

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020099067A1 (en) * 1993-07-08 2002-07-25 Ulrich Posanski Pharmaceutical compositions for sparingly soluble therapeutic agents
GB9505492D0 (en) * 1995-03-18 1995-05-03 Merck Sharp & Dohme Therapeutic agents
GB9525296D0 (en) * 1995-12-11 1996-02-07 Merck Sharp & Dohme Therapeutic agents
DE69736390T2 (de) * 1996-10-07 2007-07-26 Merck Sharp & Dohme Ltd., Hoddesdon Zns-penetrierende nk-1 rezeptorantagonisten als antidepressivum und / oder anxiolytikum
MXPA02001565A (es) * 1999-08-13 2005-07-14 Vertex Pharma Inhibidores de cinasas c-jun n-terminal (jnk) y de otras cinasas proteicas.
EP1228068A1 (en) * 1999-10-29 2002-08-07 Merck & Co., Inc. Polymorphic form of a tachykinin receptor antagonist
US20020044971A1 (en) * 2000-07-07 2002-04-18 Amidon Gordon L. Dissolution rate of poorly soluble drugs
KR100755577B1 (ko) * 2002-04-26 2007-09-12 일라이 릴리 앤드 캄파니 타키키닌 수용체 길항제로서의 트리아졸 유도체

Also Published As

Publication number Publication date
MY157375A (en) 2016-06-15
HRP20100207T1 (hr) 2010-05-31
AU2004285855B8 (en) 2011-04-28
UA82901C2 (en) 2008-05-26
US7381826B2 (en) 2008-06-03
DE602004026333D1 (de) 2010-05-12
CA2542140C (en) 2012-05-29
NO335090B1 (no) 2014-09-08
CN1863791A (zh) 2006-11-15
ES2340772T3 (es) 2010-06-09
JP4959336B2 (ja) 2012-06-20
EA200600829A1 (ru) 2006-08-25
NZ580480A (en) 2010-02-26
AU2004285855B2 (en) 2010-12-23
CL2009001310A1 (es) 2009-12-04
BRPI0415010B8 (pt) 2021-05-25
DK1675846T3 (da) 2010-05-31
BRPI0415010A (pt) 2006-11-07
JP2007509143A (ja) 2007-04-12
BRPI0415010A8 (pt) 2018-05-08
CA2542140A1 (en) 2005-05-12
NO20062371L (no) 2006-05-24
ZA200603234B (en) 2007-07-25
KR20060061388A (ko) 2006-06-07
ATE462700T1 (de) 2010-04-15
PE20050481A1 (es) 2005-09-20
US20070078166A1 (en) 2007-04-05
WO2005042515A1 (en) 2005-05-12
MA28329A1 (fr) 2006-12-01
IL174926A0 (en) 2006-08-20
CL2009001311A1 (es) 2009-10-02
NZ545917A (en) 2009-11-27
AR046131A1 (es) 2005-11-23
CR8353A (es) 2006-06-06
TW200524906A (en) 2005-08-01
KR100848407B1 (ko) 2008-07-28
BRPI0415010B1 (pt) 2019-07-09
CN1863791B (zh) 2011-12-07
EA008881B1 (ru) 2007-08-31
ECSP066517A (es) 2006-10-10
AU2004285855A1 (en) 2005-05-12

Similar Documents

Publication Publication Date Title
PT1675846E (pt) Novas formas cristalinas de {2-[1-(3,5-bis-trifluorometilbenzil)-5- iridin-4-il-1h-[1,2,3]triazol-4-il]-piridin-3-il}-(2-clorofenil)-metanona
AP2006003534A0 (en) Phenyl or pyridyl amide compounds as prostaglandin E2 antagonists.
AU2002244271A1 (en) Non-imidazole compounds as histamine h3 antagonists
PT2476667E (pt) Compostos de aminoheteroarilo como inibidores da proteína quinase
IL157732A0 (en) Atrial filter implants
IL209082A0 (en) Fushed heterocyclic compounds
PL373371A1 (en) Aryl ketone pyrrolo-triazine compounds useful as kinase inhibitors
SI1601976T1 (sl) Protokol za monitoring inhibicije trombocitov
AU2003219410A8 (en) Triaryl-oxy-aryl-spiro-pyrimidine-2, 4, 6-trione metalloproteinase inhibitors
MXPA03004540A (es) Derivados de 4-(bifenilcarbonilamino) piperidina, composiciones que los comprenden y uso de los mismos.
TWI315667B (en) Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl )piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono -hydrochloride
GB0120818D0 (en) Heterocyclic compounds
AU2003290500A1 (en) Encapsulation of ferroelectric capacitors
SI1603570T1 (sl) Spojine aminoheteroarila kot zaviralci proteinkinaze
IL151566A0 (en) Stepwise alkylation of 5-substituted 1-(4-fluorophenyl)-1,3-dihydroisobenzofurans
EG22745A (en) 2-(3,5-Disbustituted-4-pyridyl)-4-(thienyl) thiazolyl or arylphenyl)1,30xazoline compounds
PL1675846T3 (pl) Nowe krystaliczne postacie {2-[1-(3,5-bis-trifluoro-metylobenzylo)-5-pirydyn-4-ylo-1H-[1,2,3]triazol-4-ilo]-pirydyn-3-ylo}-(2-chlorofenylo)metanonu
MX252778B (es) Modificacion cristalina ii de la 2-[2 -(1-cloro- ciclopropil)- 3-(2-clorofenil)- 2 hidroxi- propil]-2, 4-dihidro -3h-1, 2, 4-triazol -3-tiona.
HK1092475A (en) Novel crystalline forms of {2-[1-(3,5-bis-trifluoromethylbenzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
AU2003250860A8 (en) Chiral 3,4-dihydro-2h-pyran compounds
AU2003260337A1 (en) Pyridinyl substituted (1,2,3,)triazoles as inhibitors of the tgf-beta signalling pathway
AU2003228950A8 (en) Oocyte recording chamber
HUP0303969A3 (en) Method for producing 2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane
HK1138834A (en) Novel intermediate and process useful in the preparation of {2-[1-(3,5-bis-trifluoromethyl-benzyl)-5-pyridin-4-yl-1h-[1,2,3]triazol-4-yl]-pyridin-3-yl}-(2-chlorophenyl)-methanone
AU2002334730A1 (en) Substituted 3-pyridyl imidazoles as c17,20 lyase inhibitors